Australian Open Ban Ignites Debate (Image Credits: Unsplash)
The French Open has taken a significant step toward integrating technology into tennis by allowing players to wear fitness trackers like WHOOP during matches. Tournament director Amélie Mauresmo revealed the decision during a press conference on April 16, 2026.[1][2] This trial marks the first time such devices gain approval at a Grand Slam event. The move responds to player demands and follows a heated dispute at the Australian Open earlier this year.
Australian Open Ban Ignites Debate
High-profile players faced unexpected hurdles at the 2026 Australian Open. Carlos Alcaraz removed his WHOOP band from under his wristband before a fourth-round match against Tommy Paul. Jannik Sinner, the men’s world No. 2, and Aryna Sabalenka, the women’s world No. 1 and WHOOP ambassador, also had to take off their devices ahead of their respective matches.[3][4]
Sabalenka voiced her frustration after her quarterfinal. She explained that players received ITF approval emails and wore the bands throughout the WTA season. “It’s just for tracking my health,” she said. “I don’t understand why Grand Slams are not allowing us to wear it, and I really hope that they will reconsider.”[2] Sinner emphasized the post-match value of the data for training adjustments, such as heart rate and calorie burn. Tennis Australia confirmed wearables remained prohibited at Grand Slams despite ongoing discussions.[1]
WHOOP Technology: Approved Yet Controversial
WHOOP bands track essential metrics without screens or communication features. Devices monitor heart rate, heart rate variability, recovery scores, strain, blood oxygenation, skin temperature, respiratory rate, sleep, and blood pressure. The International Tennis Federation approved WHOOP models (3.0, 4.0, 5.0, MG) for in-match use last year, provided haptic feedback like vibrations stays disabled.[2][4]
Players use these insights on ATP and WTA tours, where ATP permitted wearables in July 2024. WHOOP serves as the WTA’s official wearable partner since 2021. The company pushed back against the Australian Open ban. CEO Will Ahmed declared, “Data is not steroids.” WHOOP likened the restriction to “asking athletes to play blind,” arguing it poses no safety or fairness risks.[1]
- Heart rate and variability for real-time strain assessment
- Recovery scores to guide training intensity
- Sleep and respiratory data for overall health monitoring
- Skin temperature and blood oxygenation for early fatigue detection
- No live notifications or screens to ensure competitive integrity
French Open’s Trial Sets New Precedent
Mauresmo highlighted player feedback as central to the decision. “We want to provide the players with the best possible experience and we listen to their requests,” she stated. “Once again, the aim is to improve players’ performance.” The trial permits connected devices for the first time at Roland Garros, starting next month.[1]
Tournament organizers view the data access as a tool to enhance recovery and preparation. WHOOP welcomed the news as an “important milestone.” The company reaffirmed its commitment: “Access to accurate, non-invasive insights does not undermine competition. It strengthens the sport and supports players.” This shift balances tradition with modern athlete needs on clay courts.[4]
Broadening Impact on Grand Slam Tennis
The French Open initiative extends beyond Paris. Wimbledon and US Open spokespeople confirmed participation in the trial later this year. Australian Open officials had already signaled potential changes post-controversy. These developments align Grand Slams closer to tour-level policies.[1]
Players stand to gain personalized analytics during majors. Alcaraz sought data for recovery after intense matches. Sinner valued it for practice optimization. As tennis evolves, wearables could standardize performance tracking across events. Yet officials monitor for any fairness issues.[2]
Key Takeaways
- French Open leads with a trial allowing WHOOP and similar devices, driven by player advocacy.
- Australian Open incidents with Alcaraz, Sabalenka, and Sinner exposed policy gaps despite ITF approval.
- Data focuses on health metrics like recovery and strain, with no real-time coaching risks.
This trial at the French Open represents more than equipment approval. It signals tennis’s willingness to harness data for player welfare amid growing demands for transparency in performance science. Grand Slams now prioritize athlete insights, potentially reshaping preparation strategies for years ahead. What do you think about wearables on the court? Tell us in the comments.
